ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

NCT05115500 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Solid Tumor

Interventions

DRUG: ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2

Sponsor

Second Affiliated Hospital of Soochow University